According to CRI’s market research, transplantation has become an important way to save the lives of patients with critical diseases such as liver failure and kidney failure. Human organ transplantation in China began to be performed in the 1960s and grew more mature in 1990s. The number of organ transplants kept increasing and the survival rates of patients and grafts rose significantly. The annual number of organ transplants in China increased from 5,000 many years ago to more than 20,000 in 2018. Able to transplant livers, kidneys, hearts, lungs, small intestines and perform simultaneous pancreas-kidney transplants and multiple-organ transplants, China became the country second only to the United States in terms of the number of organ transplants, and is expected to become the country with the largest number of organ transplants in 2020. The increasing number of organ transplants in China greatly expands the market of immunosuppressive drugs that organ transplant recipients need to take for life.
With wider clinical application of new immunosuppressant, the market size of immunosuppressants in China exceeded CNY 15 billion in 2018.
Since the Chinese government announced the suspension of using the organs of condemned prisoners for organ transplantation in 2015, organ donation became the only legal source of supply. However, affected by traditional mind, most Chinese people are reluctant to donate their organs. The undersupply of transplant organs cannot be addressed in the short term, which creates a breeding ground for the black-market trade in organs.
According to CRI’s market research, although facing challenges, the annual number of organ transplantation is estimated to be more than 40 thousand according to CRI, and the market of immunosuppressants is expected to be over CNY 30 billion by 2024.
Topics covered:
Introduction
Development Environment
Development Status in China
Relevant Market
Prospect of China's Organ Transplant Industry
'
1 Introduction
1.1 Definition
1.2 Classification
1.3 Research Methods of the Report
1.3.1 Parameters and Assumptions
1.3.2 Data Sources
1.4 About CRI
2 Development Environment
2.1 External Environment
2.1.1 Economy Environment
2.1.2 Policy Environment
2.2 Qualified Hospitals
2.2.1 The Oriental Organ Transplant Center of Tianjin First Central Hospital
2.2.2 The Department of Hepatic Surgery of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
2.2.3 The Second Xiangya Hospital of Central South University
2.2.4 The West China Hospital of Sichuan University
2.2.5 The First Affiliated Hospital of Zhejiang University School of Medicine
2.2.6 Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (Institute of Organ Transplantation, Tongji Hospital, Huazhong University of Science and Technology)
2.2.7 The First Affiliated Hospital of Sun Yat-sen University
3 Development Status in China
3.1 Development of Organ Transplantation in China
3.2 Major Types of Organ Transplants in China
3.2.1 Kidney Transplants
3.2.2 Liver Transplants
3.2.3 Heart Transplants
3.2.4 Lung Transplants
3.3 Organ Transplantation Costs
3.4 Illegal Organ Transplantation
3.5 Foreigners Receiving Organ Transplants in China
4 Relevant Market
4.1 Immunosuppressive Drugs
4.1.1 Definition
4.1.2 Classification
4.2 Overview of immunosuppressant Market
5 Prospect of China's Organ Transplant Industry
5.1 SWOT Analysis
5.1.1 Driving Forces and Opportunities
5.1.2 Threats and Challenges
5.2 Development Direction
5.2.1 Developing xenotransplantation
5.2.2 Promoting organ donation by legislation
5.3 Forecast on Market Size, 2020-2024
5.3.1 Forecast on Number of Organ Transplants
5.3.2 Forecast on Market Size of Immunosuppressants
Selected Charts
Chart per capita income and consumption expenditure in China, 2014-2018
Chart the Number of Organ Donation and Transplantation in China, 2014-2018
Chart the Surviving Rate after Organ Transplantation in China, 2018
Chart Forecast on Number of Legal Organ Donations and Transplants in China, 2020-2024
Chart Forecast on Market Size of Immunosuppressants, 2020-2024 (Unit: CNY Billion)
